Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma

Cancer Research

Volumn 58, Issue 3, 1998, Pages 479-484

  Bischoff, Eric D ^a   Gottardis, Marco M ^a   Moon, Thomas E ^a   Heyman, Richard A ^a   Lamph, William W ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; BROXURIDINE; LIGAND; METHYLNITROSOUREA; RETINOID X RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR DIFFERENTIATION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TAMOXIFEN; TETRAHYDRONAPHTHALENES; TRANSCRIPTION FACTORS;

EID: 0032006028     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Jordan, V. C. Third annual William L. McGuire Memorial Lecture. Studies on the estrogen receptor in breast cancer - 20 years as a target for the treatment and prevention of cancer. Breast. Cancer Res Treat., 36: 267-285, 1995.
2. Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C. Fisher, E. R., Bowman, D. M., Deschenes, L., Dimitrov, N. V., Margolese, R. G., Robidoux, A., Shibata, H., Terz, J., Paterson, A. H., Feldman, M. I., Farrar, W., Evans, J., and Lickley, H. L. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl. Cancer Inst. (Bethesda), 88: 1529-1542, 1996.
3. Fisher, B. Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin. Oncol., 14: 1027-1039, 1996.
4. Jordan, V. C. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol., 110: 507-517, 1993.
5. Moon, R. C., Mehta, R. G., and Rao, K. V. N. Retinoids and cancer in experimental animals. In: M. B. Sporn, A. B. Roberts, and D. S. Goodman (eds.). The Retinoids: Biology, Chemistry, and Medicine, pp. 573-595. New York: Raven Press, 1994.
6. Lotan, R. Retinoids in cancer chemoprevention. FASEB J., 10: 1031-1039, 1996.
7. Lippman, S. M., Benner, S. E., and Hong, W. K. Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis. Cancer Res., 54 (Suppl.): 2025s-2028s, 1994.
8. Peck, G. L., and DiGiovanna, J. L. Synthetic retinoids in dermatology. In: M. B. Sporn, A. B. Roberts, and D. S. Goodman (eds.). The Retinoids, pp. 631-658. New York: Raven Press, Ltd., 1994.
9. Allegretto, E. A., McClurg, M. R., Lazarchik, S. B., Clemm, D. L., Kemer, S. A., Elgort, M. G., Boehm, M. F., White, S. K., Pike, J. W., and Heyman, R. A. Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. J. Biol. Chem., 268: 26625-26633, 1996.
10. Mangelsdorf, D. J., and Evans, R. M. The RXR heterodimers and orphan receptors. Cell, 83: 841-850, 1995.
11. Mangelsdorf, D. J., Kliewer, S. A., Kakizuka, A., Umesono, K., and Evans, R. M. Retinoid receptors. Recent Prog. Horm. Res., 48: 99-121, 1993.
12. Heyman, R. A., Mangelsdorf, D. J., Dyck, J. A., Stein, R. B., Eichele, G., Evans, R. M., and Thaller, C. 9-cis-Retinoic acid is a high affinity ligand for the retinoid X receptor. Cell, 68: 397-406, 1992.
13. Levin, A. A., Sturzenbecker, L. J., Kazmer, S., Bosakowski, T., Huselton, C., Allenby, G., Speck, J., Kratzeisen, C., Rosenberger, M., and Lovey, A. 9-cis-Retinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature (Lond.), 355: 359-361, 1992.
14. Boehm, M. F., Zhang, L., Badea, B. A., White, S. K., Mais, D. E., Berger, E., Suto, C. M., Goldman, M. E., and Heyman, R. A. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem., 37: 2930-2941, 1994.
15. Mukherjee, R., Davies, P. J., Crombie, D. L., Bischoff, E. D., Cesario, R. M., Jow, L., Hamann, L. G., Boehm, M. F., Mondon, C. E., Nadzan, A. M., Paterniti, J. R., Jr., and Heyman, R. A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (Lond.), 386: 407-410, 1997.
16. Gottardis, M. M., Bischoff, E. D., Shirley, M. A., Wagoner, M. A., Lamph, W. W., and Heyman, R. A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res., 56: 5566-5570, 1996.
17. Miller, V. A., Benedetti, F. M., Rigas, J. R., Verret, A. L., Pfister, D. G., Straus, D., Kris, M. G., Crisp, M., Heyman, R., Loewen, G. R., Truglia, J. A., and Warrell, R. P., Jr. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin. Oncol., 15: 790-795, 1997.
18. Moon, R. C. Vitamin A, retinoids and breast cancer. Adv. Exp. Med. Biol., 364: 101-107, 1994.
19. Anzano, M. A., Byers, S. W., Smith, J. M., Peer, C. W., Mullen, L. T., Brown, C. C., Roberts, A. B., and Sporn, M. B. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res., 54: 4614-4617, 1994.
20. Anzano, M. A., Peer, C. W., Smith, J. M., Mullen, L. T., Shrader, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Roberts, A. B., and Sporn, M. B. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl. Cancer Inst. (Bethesda), 88: 123-125, 1996.
21. Moon, R. C., Mehta, R. G., and Detrisac, C. J. Retinoids as chemopreventive agents for breast cancer. Cancer Detect. Prev., 16: 73-79, 1992.
22. Rose, D. P., and Mountjoy, K. G. Influence of thyroidectomy and prolactin suppression on the growth of N-nitrosomethylurea-induced rat mammary carcinomas. Cancer Res., 43: 2588-2591, 1983.
23. Mehta, C. R., and Patel, N. R. A network algorithm for performing Fisher's exact test in RXC contingency tables. J. Am. Stat. Assoc., 78: 427-434, 1983.
24. Gottardis, M. M., and Jordan, V. C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47: 4020-4024, 1987.
25. Jordan, V. C., and Allen, K. E. Evaluation of the antitumour activity of the non- steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer. 16: 239-251, 1980.
26. Wakeling, A. E., and Valcaccia, B. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens. J. Endocrinol., 99: 455-464, 1983.
27. Teelmann, K., Tsukaguchi, T., Klaus, M., and Eliason, J. F. Comparison of the therapeutic effects of a new arotinoid, Ro 40-8757, and all-trans- and 13-cis-retinoic acids on rat breast cancer. Cancer Res., 53: 2319-2325, 1993.
28. Abou-Issa, H., Dwivedi, C., Curley, R. W., Jr., Kirkpatrick, R., Koolemans-Beynen, A., Engineer, F. N., Humphries, K. A., el-Masry, W., and Webb, T. E. Basis for the anti-tumor and chemopreventive activities of glucarate and the glucarate:retinoid combination. Anticancer Res., 13: 395-399, 1993.
29. Sheikh, M. S., Shao, Z. M., Li, X. S., Dawson, M., Jetten, A. M., Wu, S., Conley, B. A., Garcia, M., Rochefort, H., and Fontana, J. A. Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-α acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem., 269: 21440-21447, 1994.
30. Kizaki, M., Dawson, M. I., Heyman, R., Elster, E., Morosetti, R., Pakkala, S., Chen, D. L., Ueno, H., Chao, W., Morikawa, M., Ikeda, Y., Heber, D., Pfahl, M., and Koeffler, H. P. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood, 87: 1977-1984, 1996.
31. Nagy, L., Thomazy, V. A., Shipley, G. L., Fesus, L., Lamph, W., Heyman, R. A., Chandraratna, R. A., and Davies, P. J. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol. Cell. Biol., 15: 3540-3551, 1995.
32. Agarwal, C., Chandraratna, R. A., Teng, M., Nagpal, S., Rorke, E. A., and Eckert, R. L. Differential regulation of human ectocervical epithelial cell line proliferation and differentiation by retinoid X receptor- and retinoic acid receptor-specific retinoids. Cell Growth Differ., 7: 521-530, 1996.
33. Nunez, S. B., Medin, J. A., Braissant, O., Kemp, L., Wahli, W., Ozato, K., and Segars, J. H. Retinoid X receptor and peroxisome proliferater-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol. Cell. Endocrinol., 127: 27-40, 1997.
34. Welsch, C. W. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res., 45: 3415-3443, 1985.
35. Sukumar, S., McKenzie, K., and Chen, Y. Animal models for breast cancer. Mutat. Res., 333: 37-44, 1995.
36. Sukumar, S., Notario, V., Martin-Zanca, D., and Barbacid, M. Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature (Lond.), 306: 658-661, 1983.
37. Manni, A., Wei, L., Badger, B., Zaenglein, A., Leighton, J., Shimasaki, S., and Ling, N. Expression of messenger RNA for insulin-like growth factors and insulin-like growth factor binding proteins by experimental breast cancer and normal breast tissue in vivo. Endocrinology, 130: 1744-1746, 1992.
38. Rosen, N., Yee, D., Lippman, M. E., Paik, S., and Cullen, K. J. Insulin-like growth factors in human breast cancer. Breast Cancer Res. Treat., 18 (Suppl. 1): S55-S62, 1991.
39. Osborne, C. K., Jarman, M., McCague, R., Coronado, E. B., Hilsenbeck, S. G., and Wakeling, A. E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother. Pharmacol., 34: 89-95, 1994.
40. Wiebe, V. J., Osborne, C. K., Fuqua, S. A., and DeGregorio, M. W. Tamoxifen resistance in breast cancer. Crit. Rev. Oncol. Hematol., 14: 173-188, 1993.
41. Gottardis, M. M., Lamph, W. W., Shalinsky, D. R., Wellstein, A., and Heyman, R. A. The efficacy of 9-cis-retinoic acid in experimental models of cancer. Breast Cancer Res. Treat., 38: 85-96, 1996.
42. Palkowitz, A. D., Glasebrook, A. L., Thrasher, K. J., Hauser, K. L., Short, L. L., Phillips, D. L., Muehl, B. S., Sato, M., Sheller, P. K., Cullinan, G. J., Pell, T. R., and Bryant, H. U. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]-phenoxy]-2-(4-hydroxyphenyl)]benzo[b] thiophene: a novel, highly potent, selective estrogen receptor modulator. J. Med. Chem., 40: 1407-1416, 1997.
43. Grese, T. A., Cho, S., Finley, D. R., Godfrey, A. G., Jones, C. D., Lugar, C. W., Martin, M. J., Matsumoto, K., Pennington, L. D., Winter, M. A., Adrian, M. D., Cole, H. W., Magee, D. E., Phillips, D. L., Rowley, E. R., Short, L. L., Glasebrook, A. L., and Bryant, H. U. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem., 40: 146-167, 1997.